Thioridazine tablets Rx
Generic Name and Formulations:
Thioridazine HCl 10mg, 25mg, 50mg, 100mg; tabs.
Various generic manufacturers
Indications for Thioridazine tablets:
Schizophrenia unresponsive to (preferably 2) other antipsychotic drugs.
Initially 50–100mg three times daily; may increase gradually to max 800mg/day in 2–4 divided doses.
Initially 0.5mg/kg per day in divided doses; may increase gradually to max 3mg/kg per day.
History of arrhythmias. Congenital long QT syndrome. QTc interval >450msec. Concomitant drugs that prolong QTc interval, CYP2D6 inhibitors (eg, fluoxetine within past 5 weeks, paroxetine), or others that inhibit thioridazine metabolism (eg, duloxetine, fluvoxamine, propranolol, pindolol). Reduced CYP2D6 activity. Coma. CNS or bone marrow depression. Severe hyper- or hypotensive heart disease.
Discontinue if QTc interval >500msec occurs. Obtain ECG and K+ levels at baseline, then periodically (esp. after changing dose). Evaluate cardiac function if syncope, dizziness, palpitations, or other symptoms of torsade de pointes occurs. Bradycardia. Hypokalemia (correct K+ before starting). History of breast cancer. Seizure disorders. Monitor blood, liver and visual function. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy. Nursing mothers.
See Contraindications. QTc interval prolongation with CYP2D6 inhibitors (eg, fluoxetine, paroxetine) or inhibitors of thioridazine metabolism (eg, duloxetine, fluvoxamine, propranolol, pindolol). Potentiates CNS depression with alcohol, other CNS depressants. Potentiates atropine, organophosphate toxicity. Antagonizes quetiapine. May cause false (+) pregnancy test.
Drowsiness, other CNS effects, anticholinergic effects, QT prolongation, arrhythmias, hyperprolactinemia, amenorrhea, ejaculation inhibition, edema, tardive dyskinesia, neuroleptic malignant syndrome, blood dyscrasias, jaundice, gynecomastia, weight gain, pigmentary retinopathy, orthostatic hypotension, hyperpyrexia, paradoxical reaction.
Formerly known under the brand name Mellaril.
Endocrinology Advisor Articles
- Behavioral Weight Loss Interventions May Prevent Obesity
- Association Between Urine Complement Proteins and Kidney Disease, Mortality in T2D
- PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes
- Rates of Incident Type 2 Diabetes in Chronic Kidney Disease
- Availability and Affordability of Diabetes Medication Worldwide
- Bioethics Concerns Should Be a Key Element in mHealth Technology Development
- Gestational Diabetes Associated With Increased Risk for Postpartum Depression
- High Prevalence of Obstructive Sleep Apnea Syndrome May Favor Screening in Diabetes
- Update on the T2D-Dementia Link: Interview With Experts
- Dozens of Medical Groups Join Forces to Improve Diagnoses